Background: The rs1344706 single nucleotide polymorphism in the ZNF804A gene is a common variant with strong evidence for association with schizophrenia. Recent studies show an association of rs1344706 with cognitive functioning, and there is some evidence suggesting that the risk allele may increase susceptibility for a subtype of schizophrenia with relatively spared cognition. Methods: We tested the effect of rs1344706 genotype in 89 schizophrenia patients on 3 basic cognitive domains (working memory, processing speed and attention) shown to be severely impaired in schizophrenia. Also we investigated the effect of rs1344706 on the severity of neurological soft signs, subtle impairments in motor and sensory functions highly frequent in schizophrenia patients. Neurological soft signs and cognitive deficits are central features of schizophrenia and are tightly linked with clinical, social and functional outcome. Results: Our results show an association of higher rs1344706 risk allele load with improved performance on processing speed and with fewer neurological soft signs. Conclusions: Together with other studies, our findings suggest that ZNF804A is associated with a subtype of schizophrenia with better cognitive and neurological functioning. Discovery of the specific pathways through which ZNF804A is exerting this effect may lead to better prevention, diagnosis and treatment for a specific group of schizophrenia patients.

O’Donovan MC, Craddock N, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CC, Howie B, Leung HT, Hartmann AM, Moller HJ, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, Maier W, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Williams NM, Giegling I, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Gejman PV, Cichon S, Nothen MM, Gill M, Corvin A, Rujescu D, Kirov G, Owen MJ, Buccola NG, Mowry BJ, Freedman R, Amin F, Black DW, Silverman JM, Byerley WF, Cloninger CR: Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 2008;40:1053–1055.
Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;460:748–752.
Shi J, Levinson DF, Duan J, Sanders AR, Zheng Y, Pe’er I, Dudbridge F, Holmans PA, Whittemore AS, Mowry BJ, Olincy A, Amin F, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Crowe RR, Oksenberg JR, Mirel DB, Kendler KS, Freedman R, Gejman PV: Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009;460:753–757.
Riley B, Thiselton D, Maher BS, Bigdeli T, Wormley B, McMichael GO, Fanous AH, Vladimirov V, O’Neill FA, Walsh D, Kendler KS: Replication of association between schizophrenia and ZNF804A in the Irish case-control study of schizophrenia sample. Mol Psychiatry 2010;15:29–37.
Zhang R, Lu SM, Qiu C, Liu XG, Gao CG, Guo TW, Valenzuela RK, Deng HW, Ma J: Population-based and family-based association studies of ZNF804A locus and schizophrenia. Mol Psychiatry 2011;16:360–361.
Steinberg S, Mors O, Borglum AD, Gustafsson O, Werge T, Mortensen PB, Andreassen OA, Sigurdsson E, Thorgeirsson TE, Bottcher Y, Olason P, Ophoff RA, Cichon S, Gudjonsdottir IH, Pietilainen OP, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Athanasiu L, Suvisaari J, Lonnqvist J, Paunio T, Hartmann A, Jurgens G, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Breuer R, Moller HJ, Giegling I, Glenthoj B, Rasmussen HB, Mattheisen M, Bitter I, Rethelyi JM, Sigmundsson T, Fossdal R, Thorsteinsdottir U, Ruggeri M, Tosato S, Strengman E, Kiemeney LA, Melle I, Djurovic S, Abramova L, Kaleda V, Walshe M, Bramon E, Vassos E, Li T, Fraser G, Walker N, Toulopoulou T, Yoon J, Freimer NB, Cantor RM, Murray R, Kong A, Golimbet V, Jonsson EG, Terenius L, Agartz I, Petursson H, Nothen MM, Rietschel M, Peltonen L, Rujescu D, Collier DA, Stefansson H, St Clair D, Stefansson K: Expanding the range of ZNF804A variants conferring risk of psychosis. Mol Psychiatry 2011;16:59–66.
Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, Craddock N, Owen MJ, O’Donovan MC: Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2011;16:429–441.
Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ, Stone WS: The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull 2007;33:49–68.
Lencz T, Szeszko PR, DeRosse P, Burdick KE, Bromet EJ, Bilder RM, Malhotra AK: A schizophrenia risk gene, ZNF804A, influences neuroanatomical and neurocognitive phenotypes. Neuropsychopharmacology 2010;35:2284–2291.
Balog Z, Kiss I, Keri S: Znf804a may be associated with executive control of attention. Genes Brain Behav 2011;10:223–227.
Voineskos AN, Lerch JP, Felsky D, Tiwari A, Rajji TK, Miranda D, Lobaugh NJ, Pollock BG, Mulsant BH, Kennedy JL: The ZNF804A gene: characterization of a novel neural risk mechanism for the major psychoses. Neuropsychopharmacology 2011;36:1871–1878.
Hargreaves A, Morris DW, Rose E, Fahey C, Moore S, Cummings E, Tropea D, Gill M, Corvin A, Donohoe G: ZNF804A and social cognition in patients with schizophrenia and healthy controls. Mol Psychiatry 2012;17:118–119.
Walters JT, Corvin A, Owen MJ, Williams H, Dragovic M, Quinn EM, Judge R, Smith DJ, Norton N, Giegling I, Hartmann AM, Moller HJ, Muglia P, Moskvina V, Dwyer S, O’Donoghue T, Morar B, Cooper M, Chandler D, Jablensky A, Gill M, Kaladjieva L, Morris DW, O’Donovan MC, Rujescu D, Donohoe G: Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry 2010;67:692–700.
Silver H, Feldman P, Bilker W, Gur RC: Working memory deficit as a core neuropsychological dysfunction in schizophrenia. Am J Psychiatry 2003;160:1809–1816.
Dickinson D, Ramsey ME, Gold JM: Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch Gen Psychiatry 2007;64:532–542.
Luck SJ, Gold JM: The construct of attention in schizophrenia. Biol Psychiatry 2008;64:34–39.
Bombin I, Arango C, Buchanan RW: Significance and meaning of neurological signs in schizophrenia: two decades later. Schizophr Bull 2005;31:962–977.
Chan RC, Xu T, Heinrichs RW, Yu Y, Wang Y: Neurological soft signs in schizophrenia: a meta-analysis. Schizophr Bull 2010;36:1089–1104.
Giakoumaki SG, Roussos P, Pallis EG, Bitsios P: Sustained attention and working memory deficits follow a familial pattern in schizophrenia. Arch Clin Neuropsychol 2011;26:687–695.
Ojeda N, Pena J, Schretlen DJ, Sanchez P, Aretouli E, Elizagarate E, Ezcurra J, Gutierrez M: Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophr Res 2012;135:72–78.
Breton F, Plante A, Legauffre C, Morel N, Ades J, Gorwood P, Ramoz N, Dubertret C: The executive control of attention differentiates patients with schizophrenia, their first-degree relatives and healthy controls. Neuropsychologia 2011;49:203–208.
Chan RC, Xu T, Heinrichs RW, Yu Y, Gong QY: Neurological soft signs in non-psychotic first-degree relatives of patients with schizophrenia: a systematic review and meta-analysis. Neurosci Biobehav Rev 2010;34:889–896.
Whitty P, Clarke M, Browne S, McTigue O, Kamali M, Feeney L, Lane A, Kinsella A, Waddington JL, Larkin C, O’Callaghan E: Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. Psychol Med 2003;33:1479–1484.
Green MF, Kern RS, Heaton RK: Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 2004;72:41–51.
Niendam TA, Jalbrzikowski M, Bearden CE: Exploring predictors of outcome in the psychosis prodrome: implications for early identification and intervention. Neuropsychol Rev 2009;19:280–293.
First M, Spitzer R, Gibbon M, Williams J: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, Biometrics Research, New York State Psychiatric Institute, 2002.
Weckx S, Del-Favero J, Rademakers R, Claes L, Cruts M, De Jonghe P, Van Broeckhoven C, De Rijk P: novoSNP, a novel computational tool for sequence variation discovery. Genome Res 2005;15:436–442.
Swindell SR, Plasterer TN: SEQMAN. Contig assembly. Methods Mol Biol 1997;70:75–89.
Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261–276.
Wechsler D: Adult Intelligence Scale Manual (Revised). New York, The Psychological Corporation, 1981.
Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L: The Continuous Performance Test, identical pairs version (CPT-IP). 1. New findings about sustained attention in normal families. Psychiatry Res 1988;26:223–238.
Buchanan RW, Heinrichs DW: The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Res 1989;27:335–350.
Browne S, Clarke M, Gervin M, Lane A, Waddington JL, Larkin C, O’Callaghan E: Determinants of neurological dysfunction in first episode schizophrenia. Psychol Med 2000;30:1433–1441.
Arango C, Bartko JJ, Gold JM, Buchanan RW: Prediction of neuropsychological performance by neurological signs in schizophrenia. Am J Psychiatry 1999;156:1349–1357.
Barkus E, Stirling J, Hopkins R, Lewis S: The presence of neurological soft signs along the psychosis proneness continuum. Schizophr Bull 2006;32:573–577.
Donohoe G, Rose E, Frodl T, Morris D, Spoletini I, Adriano F, Bernardini S, Caltagirone C, Bossu P, Gill M, Corvin AP, Spalletta G: ZNF804A risk allele is associated with relatively intact gray matter volume in patients with schizophrenia. Neuroimage 2011;54:2132–2137.
Hashimoto R, Ohi K, Yasuda Y, Fukumoto M, Iwase M, Iike N, Azechi M, Ikezawa K, Takaya M, Takahashi H, Yamamori H, Okochi T, Tanimukai H, Tagami S, Morihara T, Okochi M, Tanaka T, Kudo T, Kazui H, Iwata N, Takeda M: The impact of a genome-wide supported psychosis variant in the ZNF804A gene on memory function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2010;153B:1459–1464.
Morar B, Dragovic M, Waters FA, Chandler D, Kalaydjieva L, Jablensky A: Neuregulin 3 (NRG3) as a susceptibility gene in a schizophrenia subtype with florid delusions and relatively spared cognition. Mol Psychiatry 2011;16:860–866.
Yang MS, Morris DW, Donohoe G, Kenny E, O’Dushalaine CT, Schwaiger S, Nangle JM, Clarke S, Scully P, Quinn J, Meagher D, Baldwin P, Crumlish N, O’Callaghan E, Waddington JL, Gill M, Corvin A: Chitinase-3-like 1 (CHI3L1) gene and schizophrenia: genetic association and a potential functional mechanism. Biol Psychiatry 2008;64:98–103.
Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, Egan MF, Huffaker SS, Mattay VS, Kolachana B, Kleinman JE, Weinberger DR: Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007;117:672–682.
Gamsjaeger R, Liew CK, Loughlin FE, Crossley M, Mackay JP: Sticky fingers: zinc-fingers as protein-recognition motifs. Trends Biochem Sci 2007;32:63–70.
Kim JG, Armstrong RC, v Agoston D, Robinsky A, Wiese C, Nagle J, Hudson LD: Myelin transcription factor 1 (Myt1) of the oligodendrocyte lineage, along with a closely related CCHC zinc finger, is expressed in developing neurons in the mammalian central nervous system. J Neurosci Res 1997;50:272–290.
Nielsen JA, Berndt JA, Hudson LD, Armstrong RC: Myelin transcription factor 1 (Myt1) modulates the proliferation and differentiation of oligodendrocyte lineage cells. Mol Cell Neurosci 2004;25:111–123.
Collarini EJ, Kuhn R, Marshall CJ, Monuki ES, Lemke G, Richardson WD: Down-regulation of the POU transcription factor SCIP is an early event in oligodendrocyte differentiation in vitro. Development 1992;116:193–200.
Jaegle M, Mandemakers W, Broos L, Zwart R, Karis A, Visser P, Grosveld F, Meijer D: The POU factor Oct-6 and Schwann cell differentiation. Science 1996;273:507–510.
Wei Q, Kang Z, Diao F, Shan B, Li L, Zheng L, Guo X, Liu C, Zhang J, Zhao J: Association of the ZNF804A gene polymorphism rs1344706 with white matter density changes in Chinese schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:122–127.
Cousijn H, Rijpkema M, Harteveld A, Harrison PJ, Fernandez G, Franke B, Arias-Vasquez A: Schizophrenia risk gene ZNF804A does not influence macroscopic brain structure: an MRI study in 892 volunteers. Mol Psychiatry 2012, E-pub ahead of print.
Esslinger C, Walter H, Kirsch P, Erk S, Schnell K, Arnold C, Haddad L, Mier D, Opitz von Boberfeld C, Raab K, Witt SH, Rietschel M, Cichon S, Meyer-Lindenberg A: Neural mechanisms of a genome-wide supported psychosis variant. Science 2009;324:605.
Esslinger C, Kirsch P, Haddad L, Mier D, Sauer C, Erk S, Schnell K, Arnold C, Witt SH, Rietschel M, Cichon S, Walter H, Meyer-Lindenberg A: Cognitive state and connectivity effects of the genome-wide significant psychosis variant in ZNF804A. Neuroimage 2011;54:2514–2523.
Paulus FM, Krach S, Bedenbender J, Pyka M, Sommer J, Krug A, Knake S, Nothen MM, Witt SH, Rietschel M, Kircher T, Jansen A: Partial support for ZNF804A genotype-dependent alterations in prefrontal connectivity. Hum Brain Mapp 2011, E-pub ahead of print.
Rasetti R, Sambataro F, Chen Q, Callicott JH, Mattay VS, Weinberger DR: Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. Arch Gen Psychiatry 2011;68:1207–1217.
Walter H, Schnell K, Erk S, Arnold C, Kirsch P, Esslinger C, Mier D, Schmitgen MM, Rietschel M, Witt SH, Nothen MM, Cichon S, Meyer-Lindenberg A: Effects of a genome-wide supported psychosis risk variant on neural activation during a theory-of-mind task. Mol Psychiatry 2011;16:462–470.
Kuswanto CN, Woon PS, Zheng XB, Qiu A, Sitoh YY, Chan YH, Liu J, Williams H, Ong WY, Sim K: Genome-wide supported psychosis risk variant in ZNF804A gene and impact on cortico-limbic wm integrity in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2012;159B:255–262.
Schretlen DJ, Cascella NG, Meyer SM, Kingery LR, Testa SM, Munro CA, Pulver AE, Rivkin P, Rao VA, Diaz-Asper CM, Dickerson FB, Yolken RH, Pearlson GD: Neuropsychological functioning in bipolar disorder and schizophrenia. Biol Psychiatry 2007;62:179–186.
Myin-Germeys I, Krabbendam L, Jolles J, Delespaul PA, van Os J: Are cognitive impairments associated with sensitivity to stress in schizophrenia? An experience sampling study. Am J Psychiatry 2002;159:443–449.
Morrens M, Krabbendam L, Bak M, Delespaul P, Mengelers R, Sabbe B, Hulstijn W, van Os J, Myin-Germeys I: The relationship between cognitive dysfunction and stress sensitivity in schizophrenia: a replication study. Soc Psychiatry Psychiatr Epidemiol 2007;42:284–287.
Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR: Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003;100:6186–6191.
Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF: Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007;10:376–384.
Christie-Fougere MM, Darby-King A, Harley CW, McLean JH: Calcineurin inhibition eliminates the normal inverted U curve, enhances acquisition and prolongs memory in a mammalian 3′-5′-cyclic AMP-dependent learning paradigm. Neuroscience 2009;158:1277–1283.
Docx L, Morrens M, Bervoets C, Hulstijn W, Fransen E, De Hert M, Baeken C, Audenaert K, Sabbe B: Parsing the components of the psychomotor syndrome in schizophrenia. Acta Psychiatr Scand 2012, E-pub ahead of print.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.